2.02
5.10%
0.06
Can-Fite Biopharma Ltd ADR stock is traded at $2.02, with a volume of 88,585.
It is up +5.10% in the last 24 hours and down -28.22% over the past month.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
See More
Previous Close:
$1.96
Open:
$2
24h Volume:
88,585
Relative Volume:
0.91
Market Cap:
$11.95M
Revenue:
$743.00K
Net Income/Loss:
$-7.63M
P/E Ratio:
-0.8587
EPS:
-2.3523
Net Cash Flow:
-
1W Performance:
-2.37%
1M Performance:
-28.22%
6M Performance:
-13.45%
1Y Performance:
+4.04%
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Name
Can-Fite Biopharma Ltd ADR
Sector
Industry
Phone
972 3 924 1114
Address
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Compare CANF with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
CANF | 2.00 | 11.95M | 743.00K | -7.63M | 0 | -2.3523 |
VRTX | 467.19 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 760.91 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 566.22 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 230.54 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.55 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-11-17 | Initiated | Maxim Group | Buy |
Oct-19-16 | Resumed | ROTH Capital | Buy |
Aug-29-16 | Resumed | Rodman & Renshaw | Buy |
Nov-30-15 | Reiterated | H.C. Wainwright | Buy |
Mar-31-15 | Reiterated | H.C. Wainwright | Buy |
Mar-30-15 | Downgrade | ROTH Capital | Buy → Neutral |
Dec-29-14 | Reiterated | ROTH Capital | Buy |
Nov-18-14 | Initiated | H.C. Wainwright | Buy |
View All
Can-Fite Biopharma Ltd ADR Stock (CANF) Latest News
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial - GlobeNewswire Inc.
Can-Fite secures Australian patent for obesity treatment - Investing.com
Can-Fite's partner Vetbiolix secures $325M deal for dog arthritis drug - Investing.com India
Ratios in Focus: Analyzing Can-Fite Biopharma Ltd ADR (CANF)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What is CANF’s price-to-sales ratio telling us about the company’s value? - US Post News
Taking on analysts’ expectations and winning: Can-Fite Biopharma Ltd ADR (CANF) - SETE News
Analytical Lens: Exploring Can-Fite Biopharma Ltd ADR (CANF)’s Financial Story Through Ratios - The Dwinnex
CANF (Can-Fite Biopharma Ltd ADR) has impressive results - US Post News
List of Israeli Stocks Traded on the NYSE Worth Considering - The Times of Israel
Wearable Devices Ltd. sets annual meeting for September 26 - Investing.com
Can-Fite BioPharma shares upgraded by EF Hutton to Buy on pipeline drugs - Investing.com
GitLab stock maintains buy rating on new release By Investing.com - Investing.com
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat - Yahoo New Zealand News
Canine arthritis treatment shows promise in clinical study - Investing.com India
Can-Fite reveals adiponectin role in cancer treatment By Investing.com - Investing.com
Was Can-Fite Biopharma Ltd ADR (CANF)'s session last reading good? – US Post News - US Post News
Can-Fite's Namodenoson gains FDA Fast Track for liver cancer - Investing.com India
Can-Fite's Namodenoson gains FDA Fast Track for liver cancer By Investing.com - Investing.com
Can-Fite's Namodenoson advances in Phase III liver cancer trial By Investing.com - Investing.com
Can-Fite BioPharma seeks FDA nod for NASH drug trial By Investing.com - Investing.com
ANVS Stock Quote Price and Forecast - CNN
symbol__ Stock Quote Price and Forecast - CNN
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire
Can-Fite Announces ADS Ratio Change - Business Wire
Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates - Nasdaq
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma - Business Wire
Best Penny Stocks Today | Penny Stocks to Buy Now -TipRanksTipRanks.com - TipRanks
The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Trea - Benzinga
Can-Fite BioPharma (CANF) Stock Price, News & Analysis - MarketBeat
The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And Mo - Benzinga
32 Stocks Moving In Thursday's Mid-Day SessionAEterna Zentaris (NASDAQ:AEZS), ADMA Biologics (NASDAQ:A - Benzinga
10 Biopharmaceutical Companies Trying To Cure Cancer - Yahoo Finance
The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax OfferingiShares B - Benzinga
Secondary Offerings Put A Pause On May's MomentumMynd.ai (AMEX:MYND), Can Fite Biofarma (AMEX:CANF) - Benzinga
28 Stocks Moving In Monday's Pre-Market Session - Benzinga
20 Biggest Mid-Day Gainers For TuesdayAlcoa (NYSE:AA), Biogen (NASDAQ:BIIB) - Benzinga
Can-Fite's Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III Trial For $40 Billion Market (NYSE:CANF) - Seeking Alpha
Propanc Health Group Corp : This Company Could Be the Next CETX or CANF - Marketscreener.com
Morning Market GainersCan Fite Biofarma (AMEX:CANF) - Benzinga
Can-Fite BioPharma Begins Trading in U.S. through Launch of ADRs - CNBC
Can-Fite Biopharma Ltd ADR Stock (CANF) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):